hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions

Background Gastric cancer is a serious public health problem in Northern Brazil and in the world due to its high incidence and mortality. Despite the severity of the disease, more research is needed to better understand the molecular events involved in this intestinal-type gastric carcinogenesis process. Since precancerous lesions precede intestinal-type gastric cancer, here, we evaluated the hTERT, MYC, and TP53 mRNA and protein expression, as well as TP33 copy number, in gastric preneoplastic lesions. Methods We evaluated 19 superficial gastritis, 18 atrophic gastritis, and 18 intestinal metaplasia from cancer-free individuals of Northern Brazil. Quantitative reverse transcription PCR was used to analyze the mRNA expression and immunohistochemical methods were used to assess protein immunoreactivity in tissue samples. The number of TP53 gene copies was investigated in gastric diseases by quantitative PCR. Results We observed hTERT, MYC, and p53 immunoreactivity only in intestinal metaplasia samples. The immunoreactivity of these proteins was strongly associated with each other. A significantly higher MYC mRNA expression was observed in intestinal metaplasia compared to gastritis samples. Loss of TP53 was also only detected in intestinal metaplasia specimens. Conclusions We demonstrated that hTERT, MYC, and TP53 are deregulated in intestinal metaplasia of individuals from Northern Brazil and these alterations may facilitate tumor initiation.


Background
Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide [1]. In Northern Brazil, gastric cancer is the second most frequent neoplasia among males and the third in females [2]. Some histopathological lesions precede welldifferentiated or intestinal-type gastric cancer. These neoplasia types progress through a number of sequential steps beginning with superficial gastritis, followed by chronic atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia, and finally, carcinoma [3]. Although this neoplasia is a serious public health problem in Northern Brazil and in the world, little is known about the molecular events involved in the gastric carcinogenesis process. A better understanding of the critical alterations implicated in tumor initiation is necessary to reduce the mortality rates through early diagnosis and treatment.
Cell immortalization has been reported as an important event in carcinogenesis. This process requires activation of telomerase, an enzyme essential for stabilizing telomere length. Telomerase activation is described in about 90% of human cancers, while most normal tissues contain inactivated telomerase [4]. In the absence of genome checkpoint functions, telomere dysfunction accelerates genomic instability, facilitating tumor initiation [5]. This genomic instability caused by telomere dysfunction occurs in the early stages of carcinogenesis, before telomerase activation. Subsequently, telomeres in these initiated cells undergo further progressive shortening, generating rampant chromosomal instability and threatening cell survival. Telomerase activation occurs at this stage to stabilize the genome and confer unlimited proliferative capacity upon the emerging and evolving cancer cell. Therefore, cells that have acquired telomerase activity can obtain the capacity for cancer progression [6].
Transcriptional regulation of hTERT (the catalytic subunit of telomerase) gene is the major mechanism for cancer-specific activation of telomerase. Several factors have been reported to directly or indirectly regulate the hTERT promoter, including cellular transcriptional activators, such as MYC, as well as the repressors, such as p53 (see review [6]).
The MYC proto-oncogene has been described as a key in the gastric carcinogenic process [7]. MYC protein has an effect on about 15% of genes in the human genome [8]. MYC activates several genes involved in cell cycle regulation, metabolism, ribosome biogenesis, protein synthesis, and mitochondrial function, while it consistently represses genes involved in cell growth arrest and cell adhesion, and also has a direct role in the control of DNA replication [9]. Among the MYC target genes are hTERT as well as TP53 [9].
TP53 is a key tumor suppressor gene in the carcinogenesis process [10] acting in the DNA damage response and apoptosis, as well as a regulator of cell metabolism [11]. TP53 somatic alteration is described in approximately 50% of human cancers, including gastric cancer [10]. Moreover, the loss of the TP53 locus is a common finding in gastric neoplasias of individuals from Northern Brazil [12].
The aim of the present study was to determine whether hTERT, MYC, and TP53 mRNA expression, as well as their protein products, are deregulated in gastric preneoplastic lesions from cancer-free individuals of Northern Brazil. The number of TP53 gene copies was also evaluated in gastric diseases.
One sample of superficial gastritis presented 3 copies of TP53 and this case was excluded from the CNV statistical analyses. Loss of TP53 copies was observed only in the group of intestinal metaplasia samples ( Table 1). The frequency of TP53 loss was significantly higher in intestinal metaplasia samples compared to gastritis specimens (χ 2 = 6.353, df = 1, p = 0.033, by Fisher exact test, V = 0.343, OR = 2.4). The loss of TP53 copies was associated with hTERT (χ 2 = 18.265, df = 1, p = 0.002, V = 0.582; OR = 1.6) and p53 (χ 2 = 9.926, df = 1, p = 0.03, V = 0.429, OR = 1.47) immunoreactivity. However, this analysis should be considered with care since only 3 cases presented loss of TP53 copies.

Discussion
Telomerase activation is thought to be essential for the stabilization of telomere length, through which immortalization and oncogenesis are achieved, but little is known about the regulation of the hTERT subunit in human precancerous gastric lesions. In the present study, we observed that hTERT, MYC, and p53 immunoreactivity was only present in intestinal metaplasia samples. In addition, we detected a strong association among these three proteins and 27.8% of intestinal metaplasia samples presented immunostaining of the three studied proteins. MYC is a transcriptional activator and p53 is a repressor of hTERT expression [6]. Some studies favored the view that MYC drove initial proliferation and subsequent differentiation, concomitant with the activation of the p53 G2 checkpoint and also demonstrated that inactivation of the p53-Rb pathway is required for immortalization through overepression of MYC [13,14]. Thus, some cases of intestinal metaplasia may carry short telomeres and due to this telomere dysfunction, MYC stimulates hTERT expression. However, in the absence of genome checkpoint functions (i.e. p53 mutations or TP53 deletion), this process will favor the proliferation of immortalized cells carrying genetic and epigenetic alterations and tumor initiation.
It is important to note that, although intestinal metaplasia precedes intestinal-type gastric cancer, only few individuals with this preneoplastic lesion will develop gastric tumors. Further investigation are necessary to evaluate the role of hTERT, MYC, and p53 proteinsalterations common described in gastric neoplasiain the disease progression, ideally with biopsies of intestinal metaplasia and tumor from the same patients. These biomarkers may be useful for the assessment of gastric cancer risk if validated in a larger clinical study sets.
Some studies demonstrated that hTERT expression increases with the sequential steps of intestinal-type gastric carcinogenesis [15][16][17][18][19], suggesting that hTERT deregulation represents an important step in the carcinogenesis progress. We also previously demonstrated that 80% of gastric tumors and no nonneoplastic gastric mucosa of individuals from Northern Brazil presented hTERT immunoreactivity, suggesting that hTERT may have an impact on the anti-telomerase strategy for cancer therapy [20].
The detection of MYC immunoreactivity in intestinal metaplasia of individuals from three Northern Brazil populations corroborates previous studies of our group that demonstrated the presence of MYC protein overexpression only in intestinal metaplasia and neoplastic tissue from all patients with intestinal type gastric cancer, which is preceded by preneoplastic lesions [21][22][23], as well as in intestinal metaplasia of non-human primates treated with N-methyl-nitrosourea (MNU) [24]. On the other hand, MYC immunoreactivity was described in gastritis samples, as well as intestinal metaplasia, in Asian populations [15,[25][26][27].
Here, MYC immunoreactivity was strongly associated with increased mRNA expression. To our knowledge, this is the first study to sensitively quantify MYC mRNA expression in precancerous gastric lesions. The increased MYC expression in intestinal metaplasia supports a previous study of our group in non-human primates, in  which we demonstrated a continuous increase of MYC mRNA expression during the sequential steps of gastric carcinogenesis in MNU-treated animals [24]. In these animals, the mRNA expression increased about 3-fold in intestinal metaplasia compared to normal gastric mucosa. In addition, we previously reported that a significant increase of MYC copy number was seen with the evolution of carcinogenesis process in humans and nonhuman primates [21,24], which may contribute to the increased mRNA expression and protein immunoreactivity. In addition, MYC amplification or trisomy of chromosome 8, where MYC is located, was detected in all human gastric cancer of individuals from Northern Brazil [21][22][23][28][29][30][31], as well as in gastric cancer cell lines established from the tumors of Brazilian patients [32][33][34][35], supporting that MYC has a key role in gastric carcinogenesis.
Previously we also reported the presence of p53 immunoreactivity in all intestinal-type gastric cancer of individuals from Northern Brazil [12]. The p53 immunoreactivity usually depends on the accumulation of mutated p53 proteins in the cell, which leads to a longer half-life [36]. Some studies have demonstrated TP53 mutations in gastritis [37] and intestinal metaplasia [38,39] as well as gastric cancer, which corroborates the observation of p53 immunoreactivity in intestinal metaplasia samples of the studied population. The presence of p53 immunostaining only in intestinal metaplasia corroborates previous studies of literature [15,40]. However, Targa et al. [41] reported p53 overexpression in 5/19 (26.3%) of chronic gastritis, 1/8 (12.5%) of atrophic gastritis and 2/11 (18.2%) of intestinal metaplasia of individuals from Southeastern Brazil.
To our knowledge, few studies evaluated the number of copies of TP53 in pre-neoplastic gastric lesions. Loss of heterozygosity at the TP53 locus is one of the most common mechanisms involved in this gene pathway deregulation. Loss of TP53 is a frequent finding in gastric cancer [42]. Previously, our group demonstrated that the loss of TP53 copies and aneusomy of chromosome 17, where this gene is located, was present in all gastric cancer samples of individuals from Pará State, Northern Brazil [12], and also in all gastric cancer cell lines established from neoplasias in this population [33,43]. Here, we observed TP53 deletion in 16.7% of intestinal metaplasia in individuals from Northern Brazil by qPCR. In a Southeastern Brazilian population, it was described that 3/5 (60%) of intestinal metaplasia samples presented loss of TP53 by fluorescence in situ hybridization (FISH) assay [36]. Williams et al. [42] also reported that the deletion of TP53 was a common event in premalignant stages of gastric carcinogenesis by FISH analyses. These authors demonstrated that this alteration was about 3fold increased in intestinal metaplasia (N = 4) compared to normal gastric tissue. Since TP53 is a critical tumor suppressor gene in the carcinogenesis process, the loss of this gene copy and its protein immunoreactivity in the intestinal metaplasia stage may contribute for tumor initiation.

Conclusions
In conclusion, hTERT, MYC, and TP53 are deregulated in intestinal metaplasia of individuals from Northern Brazil and these alterations may facilitate tumor initiation.

Clinical samples
Samples were obtained from cancer-free patients including 19 with superficial gastritis, 18 with atrophic gastritis, and 18 patients with intestinal metaplasia by endoscopy. From each patient, normal tissue sample were also collected. Samples were collected at endoscopy services in Pará, Maranhão and Ceará States in Northern Brazil. Informed consent with approval of the ethics committee of the Federal University of Pará was obtained. Tissue specimens were immediately frozen in liquid nitrogen and kept at −80°C until RNA and DNA extraction. All studied samples were negative for Epstein-Barr infection by in situ hybridization method [44]. The presence of Helicobacter pylori, a class I carcinogen, in gastric samples was detected by the PCR assay for the urease gene [45]. Table 1 shows the clinicopathological characteristics of patients.

mRNA expression
Total RNA was extracted with Tri-reagent (Applied Biosystems, USA) following the manufacturer's instructions. RNA concentration and quality were determined using the NanoDrop spectrophotometer (Kisker, Germany) and 1% agarose gels. Complementary DNA was synthesized using High-Capacity cDNA Archive (Applied Biosystems, Poland).
hTERT, MYC, and TP53 mRNA expression was evaluated by quantitative reverse transcription PCR (qRT-PCR) with primers and TaqMan probes purchased as Assays-on-demand Products for Gene Expression (Applied Biosystems, USA). GAPDH gene was selected as an internal control for RNA input and reverse transcription efficiency. All real-time qRT-PCR reactions were performed in triplicate for all target genes (hTERT: Hs00972656_m1; MYC: Hs00153408_m1; TP53: Hs01034249_m1) and the internal control (GAPDH: NM_002046.3).
Relative quantification (RQ) of the gene expression was calculated according to Livak and Schmittgen [46]. In the present study, the corresponding normal tissue sample was designated as a calibrator for superficial gastritis, atrophic gastritis, or intestinal metaplasia sample from each patient.

TP53 copy number variation (CNV)
Quantitative TaqMan CNV assays (Applied Biosystems, USA) were used as a confirmation to FISH analysis. Duplex quantitative PCR (qPCR) was performed using the FAM/MGB-labeled TaqMan probe for TP53 gene (Hs06423639_cn) and VIC/TAMRA-labeled TaqMan CNV RNAse P (#4403326) for the internal control. qPCR reactions were performed in quadruplicate with genomic DNA (gDNA) according to the manufacturer's protocol and cycling conditions in 7500 Fast Real-Time PCR (Applied Biosystems, USA). Relative quantification analysis was done to estimate the copy number for each sample by using the Copy Caller Software V1.0 (Applied Biosystems, USA). A known human gDNA (Promega, USA) was used for calibration.

Data analysis
Chi-square test was performed to analyze hTERT, MYC, and p53 immunostaining, as well as TP53 CNV data. To take into account the multiple testing, Bonferroni corrections were applied to adjust the Chi-squared p value when necessary. Shapiro-Wilk normality test was used to evaluate the normal distribution of mRNA expression data and to determine subsequent use of appropriate tests for statistical comparison. Data that were not normally distributed were transformed (z-score transformation) for the analysis of variance in gene expression such that they followed a normal distribution. Analyses of variance in mRNA expression were performed by one-way ANOVA followed by Tukey (homogeneity of variances according to Levene test) post-hoc test. Chisquare and Student's T test were used to assess the relationship between gene expression, protein immunoreactivity, and CNV results and clinicopathological factors.
The effect size for Chi-square was based on Cramer's phi (V) and the effect size correlation directly from the Student T test as "r" (Pearson correlation coefficient), in which a value between 0.1-0.29 was determined as a small effect size; 0.3-0.49 as a medium effect size; and 0.50 or above as a large effect size. The effect size for ANOVA analyses was based on Eta Squared (η 2 ), in which values 0.15 and below were determined as a small effect size; 0.16-0.40 as a medium effect size; and above 0.40 as a large effect size.
The correlation between hTERT, MYC, and TP53 mRNA expression was analyzed by the Pearson test, in which a value below 0.30 was determined as a weak correlation; 0.30-0.70 as a medium correlation; and above 0.70 as a strong correlation.
In all analyses, the confidence interval was 95% and p values less than 0.05 were considered significant.